Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.
Hospital Pharmacy, Kantonsspital Baden, Baden, Switzerland.
Swiss Med Wkly. 2024 Aug 18;154:3391. doi: 10.57187/s.3391.
Opioid prescriptions have increased in Switzerland, even though current guidelines warn of their harms. If opioids for postoperative analgesia are not tapered before hospital discharge, patients are at risk of adverse events such as constipation, drowsiness, dependence, tolerance and withdrawal. The aim of this study was to investigate and quantify the potential association between opioids prescribed at discharge from hospital and rehospitalisation.
We conducted a nested case-control study using routinely collected electronic health records from a Swiss public acute hospital. Cases were patients aged 65 years or older admitted between November 2014 and December 2018, with documented opioid administration on the day of discharge and rehospitalisation within 18 or 30 days after discharge. Each case was matched to five controls for age, sex, year of hospitalisation and Charlson Comorbidity Index. We calculated odds ratios for 18-day and 30-day rehospitalisation based on exposure to opioids using a conditional logistic regression adjusted for potential confounders. Secondary analyses included stratifications into morphine-equivalent doses of <50 mg, 50-89 mg and ≥90 mg, and co-prescriptions of gabapentinoids and benzodiazepines.
Of 22,471 included patients, 3144 rehospitalisations were identified, of which 1698 were 18-day rehospitalisations and 1446 were 30-day rehospitalisations. Documented opioid administration on the day of discharge was associated with 30-day rehospitalisation after adjustment for confounders (adjusted odds ratio 1.48; 95% CI 1.25-1.75, p <0.001), while no difference was observed in the likelihood of 18-day rehospitalisation. The combined prescription of opioids with benzodiazepines or gabapentinoids and morphine-equivalent doses >50 mg were rare.
Patients receiving opioids on the day of discharge were 48% more likely to be readmitted to hospital within 30 days. Clinicians should aim to discontinue opioids started in hospital before discharge if possible. Patients receiving an opioid prescription should be educated and monitored as part of opioid stewardship programmes.
瑞士的阿片类药物处方量有所增加,尽管目前的指南警告其存在危害。如果术后镇痛的阿片类药物在出院前不逐渐减少剂量,患者可能会出现便秘、嗜睡、依赖、耐受和戒断等不良事件。本研究旨在调查和量化出院时开具的阿片类药物与再入院之间的潜在关联。
我们使用瑞士一家公立急性医院的常规电子健康记录进行了嵌套病例对照研究。病例为 2014 年 11 月至 2018 年 12 月期间入院、出院当天有阿片类药物使用记录且出院后 18 或 30 天内再入院的年龄在 65 岁及以上的患者。每个病例与年龄、性别、入院年份和 Charlson 合并症指数相匹配的 5 个对照进行匹配。我们使用条件逻辑回归,根据暴露于阿片类药物的情况计算了 18 天和 30 天再入院的比值比,调整了潜在混杂因素。次要分析包括按吗啡等效剂量<50mg、50-89mg 和≥90mg 分层,以及加用加巴喷丁类药物和苯二氮䓬类药物。
在纳入的 22471 名患者中,确定了 3144 例再入院,其中 1698 例为 18 天再入院,1446 例为 30 天再入院。调整混杂因素后,出院当天开具阿片类药物与 30 天再入院相关(调整比值比 1.48;95%CI 1.25-1.75,p<0.001),而 18 天再入院的可能性无差异。阿片类药物联合苯二氮䓬类药物或加巴喷丁类药物以及吗啡等效剂量>50mg 的联合处方很少见。
出院当天接受阿片类药物治疗的患者 30 天内再入院的可能性增加 48%。如果可能,临床医生应在出院前停止在医院开始的阿片类药物治疗。开具阿片类药物处方的患者应作为阿片类药物管理计划的一部分接受教育和监测。